Gastroparesis refers to a delay in emptying stomach contents.  Symptoms often include feeling full after eating a meal, or even a small amount of food, as well as nausea, vomiting, bloating or abdominal pain. The causes of gastroparesis may include diabetes mellitus, complications after surgery, kidney disease, certain medications, thyroid disorders, cancer, among others.

The following tips are intended to reduce symptoms and help maintain adequate nutrition.

Mealtime

  • Eat small, frequent meals (5-6 or more per day is recommended)
  • Start with the most nutritious foods first before consuming snacks or empty calories
  • Chew all foods well
  • Sit upright during meals and for 1-2 hours afterward

Foods

  • Limit dietary fat intake, avoiding high fat, fried or greasy foods. Liquid fat in beverages is likely better tolerated such as cream or half-and-half.
  • Limit dietary fiber intake as this slows stomach emptying and can cause gas and bloating. Look for low fiber foods with < 2 grams fiber/serving.

 


Fluids

  • Stay hydrated. Most adults need 6-10 cups of water per day. Sip slowly throughout the day.
  • Drink fluids with meals, however; be sure not to fill up on liquids
  • Avoid carbonated beverages as they can cause bloating

其他

  • Avoid alcohol as it can affect stomach emptying
  • Foods that are acidic, spicy, or contain caffeine or mint may increase acid reflux
  • Keep blood sugars under control if you have diabetes
  • Keep a food diary to track your intake and find foods that are best tolerated
  • Exercise may increase stomach emptying and reduce symptoms. Walking after meals is suggested.

See below for help in choosing more optimal foods from each food group:

 

Gastroparesis Sample Menus  

Please visit Restore+ to learn more about the nutrition support services offered by Option Care Health.

*This material is for informational purposes only. It does not replace the advice or counsel of a healthcare professional. Please consult with your Registered Dietitian for more detailed, individualized information.

Dining out at restaurants is a nice treat but also challenging when trying to stick with your therapeutic diet, especially with gastrointestinal diseases. Most restaurants have menus and nutritional information available online. Restaurants are not required to have nutrition information available if they have less than 20 locations. Follow these tips to navigate eating out if you have specialized nutrition needs.

GENERAL TIPS:

  • Research the menu online
  • Pick a cuisine you tolerate
  • Ask server for nutritional information or ingredients if not listed on the menu
  • Do NOT be afraid to ask to customize the meal or ask for specific changes
  • Communicate with wait staff if you have a food allergy or intolerance
  • HAVE A PLAN AND STICK WITH IT!

Please visit Restore+ to learn more about the nutrition support services offered by Option Care Health.

*This material is for informational purposes only. It does not replace the advice or counsel of a healthcare professional. Please consult with your Registered Dietitian for more detailed, individualized information.

Short bowel syndrome (SBS), or intestinal failure, is a condition in which your body is unable to absorb enough nutrients from foods and fluids you consume. This can occur after a surgical resection or damage to your intestines. Symptoms and absorption vary by individual based on the amount and health of the remaining intestine. Symptoms of SBS can include diarrhea, dehydration, electrolyte abnormalities, and weight loss.  

The following tips are intended to maximize absorption, improve your nutritional status and reduce dependence on parenteral nutrition. 

  • Mealtime
    • Eat small, frequent meals (6-8 per day)
  • Foods
    • Eat protein at all meals: eggs, creamy peanut butter, chicken, fish, beef, tofu
    • Choose complex carbohydrates such as bread, pasta, rice, and potatoes
    • Limit raw vegetables to small amounts
    • Avoid fruits with skin or edible seeds
    • Limit raw fruits to very small portion twice a day
    • Increase your soluble fiber to thicken output with foods such as bananas, applesauce, rice, oatmeal or use of soluble fiber supplements
    • Avoid high fat foods such as fried foods if your colon is intact
    • Use caution with dairy products – lactose intolerance is common with SBS
    • Avoid concentrated sweets such as candy, desserts, and juice
    • Avoid foods artificially sweetened with sorbitol or mannitol (Splenda® is okay)
  • Fluids
    • Drink isotonic fluids (with electrolytes), ideally oral rehydration solutions (see recipes below)
    • Do not drink fluids with meals as it increases how quickly food passes through
    • Limit to 4 oz. fluid during your meal to allow your food to be best absorbed
    • Drink ½ hour before or 2 hours after eating
    • If you do not have your colon, your fluid losses will be higher
  • 其他
    • If prescribed by your doctor, take antidiarrheal medication ½ hour before meals
    • Salty foods such as pretzels or soups are usually well tolerated and help absorb fluid
    • Avoid caffeine and alcohol

See below for help in choosing more optimal foods from each food group:

 

**For homemade ORS, discard after 24 hours if not consumed

**Visit for more recipes: https://optioncarehealth.com/patients/resources/sbs-friendly-recipes

SBS Sample Menu

Please visit Restore+ to learn more about the nutrition support services offered by Option Care Health.

*This material is for informational purposes only. It does not replace the advice or counsel of a healthcare professional. Please consult with your Registered Dietitian for more detailed, individualized information.

As a leading healthcare provider, we recognize our role and our responsibility to protect the health and safety of our patients, customers, team members and community. Option Care Health is mandating all leaders be fully vaccinated by September 30, 2021 and all patient and customer-facing team members be fully vaccinated by October 15, 2021.

“Our mission is to transform healthcare while delivering hope to our patients and their families,” said John Rademacher, Chief Executive Officer. “We believe our single largest contribution to eradicating COVID-19 is through vaccination. By receiving the vaccine, we are becoming a part of the solution. Each one of us at Option Care Health plays a critical role in our purpose of providing extraordinary care that changes lives.”

Option Care Health complies with applicable federal, state and local laws and will evaluate exceptions to the vaccine requirement due to a medical condition or strongly held religious beliefs.

BATON ROUGE, La., and BANNOCKBURN, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and personal care, and Option Care Health Inc. (NASDAQ: OPCH), the nation’s largest independent home and alternate site infusion services provider, are collaborating on providing COVID antibody infusion therapy within skilled nursing and assisted living facilities, collectively referred to as “long term care facilities.” The U.S Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) to both Eli Lilly and Regeneron for their investigational neutralizing antibody therapies to treat mild to moderate COVID-19 in adults and pediatrics who are at high risk for progressing to severe COVID-19 symptoms or hospitalization.

On December 8, 2020, the National Home Infusion Association (NHIA) announced it had launched a pilot program with Operation Warp Speed and the department of Health and Human Services to expand access to Bamlanivimab for COVID-19-positive eligible patients residing in long-term care facilities. As an active member of the NHIA, Option Care Health agreed to participate in the pilot program to help service this vulnerable population.

Through the collaboration, which will initially be piloted in Indianapolis and Valparaiso, Indiana markets, with potential to scale to other markets, as appropriate, Amedisys and Option Care Health will coordinate to expeditiously provide care to long-term care facility residents. This innovative service model draws on the strengths and capabilities of both organizations and leverages clinical resources in the most efficient way to ensure expanded access to this difficult-to-serve population. Through its Hospice division, Amedisys will oversee the on-site care coordination for residents through their expansive clinical team. Option Care Health will leverage its pharmacy network operations to provide critical clinical pharmacy oversight and will distribute Bamlanivimab through its national network of pharmacies.

John Rademacher, Chief Executive Officer of Option Care Health, stated, “We are proud to collaborate with Amedisys, a leader in home health and hospice services, along with NHIA and leaders of Operation Warp Speed, to expand access to vital therapies for one of the most vulnerable populations. Combining the extraordinary capabilities of two industry leaders to solve a critical healthcare challenge is truly humbling.”   

“We have experience from being on the frontlines and caring for more than 12,500 COVID 19-positive patients,” stated Paul Kusserow, President and Chief Executive Officer of Amedisys. “We know how important innovative solutions are for caring for those who need our services the most, and this is exactly the type of partnerships in which Amedisys wants to be involved to help our country make it through this pandemic. We’re extremely honored to play our part alongside Option Care Health, NHIA and Operation Warp Speed.”

About Amedisys

Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,600 hospitals and 67,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, Tenn., Amedisys is a publicly held company. With 21,000 employees in 514 care centers within 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 415,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com.

关于 Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including approximately 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates.

Forward-Looking Statements:
When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should,” “will” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protest or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

For Investor Inquiries:
Bob East, Asher Dewhurst, Jordan Kohnstam
Westwicke
443-213-0500
optioncarehealth@westwicke.com 

10 月 18 日至 24 日是全美药学周(National Pharmacy Week)。每年我们都会庆祝药学周,以表彰药剂师和技术人员为改善整个护理范围内的患者护理做出的宝贵贡献。最近,我们与药学团队的几位成员进行了座谈,以详细了解他们在药学和 Option Care Health 的工作经验。继续阅读以详细了解:

  • 密苏里州圣路易斯市药房技术员主管 Jamie Broome
  • 罗德岛州普罗维登斯市认证药房技术员主管 Jessica-Anne Chelbda
  • 内布拉斯加州林肯市配药药房技术员 Brad Van Egdom
  • 纽约州纽约市药房总监 Constantine (Gus) Vergidis

OCH: Tell us about how you chose to begin your career in pharmacy and how you came to work in home infusion pharmacy?

JC:到 OCH 任职之前,我曾在一家长期护理机构工作,在那里我们会对药物进行气泡包装。我们还有一间静脉注射室,我的配药之旅就从那里开始。那边的配药情况与这里截然不同。过程更为简单,主要包括注射器和简易药袋。当我开始在 OCH 工作时,我接触到了各种我之前从未见过的给药方法,因为家庭护理与在长期护理机构里有人照顾你大不相同。在那种环境下,我主要与护士打交道,他们会给患者注射药物。我相信家庭输液是我想安身立命的地方,这是我十几年来所遇到的最喜欢的药学事业。

JB:我的职业生涯从担任医院中的药房技术员开始。我曾在几家不同的医院工作过,我的一位前同事给我打电话说 OCH 有职位空缺。当时我并不打算找工作,但这似乎是个挺不错的机遇。我很喜欢在无尘室和医院里工作。我以前从未听说过家庭输液药房,但这机会难得,我很庆幸自己把握住了机会。

CV:我的药学生涯从家庭输液开始。实际上,我的职业生涯是从 Rite-Aid 的药房实习生开始的,但在获得主任药剂师执照后的第一年,我就接受了我在 Option Care Health 的第一份工作。药学院是一项长期的承诺,而零售药店并不适合将我成为药学博士时接受的所有教育学以致用。在零售业中,你只能了解到患者的一部分情况,而通过家庭输液,你可以看到患者健康历程的全貌。因此,你能够跟踪他们的进展,确保治疗有效,并帮助他们在病情好转时从服务中过渡。

BV:我是真正的制药人员,因此责任重大。我必须确保我制造的产品准确且安全。我在工作时想着患者——要是这人是我的爸爸妈妈、爷爷奶奶呢?——我会希望药物尽可能完美、安全。我在配制每一种药物时,都尽量做到细致入微,确保没有任何问题。

OCH:是什么让您决定成为一名药房技术员/药剂师?

JC:大约十年前,我打算去上护理学校,但后来生活未能如愿。我的计划有所改变,我研究了一下自己喜欢的医疗保健业的不同领域。我在寻找一种既可以亲力亲为,又不需要长时间面对患者的工作。我调查了一个药房技术员培训项目,到罗德岛州林肯市的林肯技术学院读书。求学的经历给了我极大的鼓舞,让我了解到各个领域的药学角色类型迥然不同。这些工作不仅仅涉及人们前去取药的零售药房,这并不是药房技术员求职的唯一选择。在我看来,选项丰富多样,随着我的经验积累,我能够在这些选项中自由探索,直至找到我真正热爱的工作。

JB:我当时考虑过去药学院读书,但担心需要投入大量的时间,不确定自己是否会喜欢。我从社区大学开始起步,决定在第一学期转学药房技术员课程。

CV:选择成为一名药剂师很容易。我一直想帮助别人,尤其是有病和有需要的人。我本来想当医生或律师,但因为能够影响到患者,所以最终选择了药学。我从小对药学也很感兴趣,这也过渡到了我后来的职业。

BV: 其实我的职业生涯是从零售业开始的,有人问我是否想转入药学行业,这并不是我原本想做的事情。我之前并没有什么经验,但我在寻找新的体验。每当我有机会挑战自我并尝试一些新事物时,我都会全力以赴。这就是我所做的,最终我非常喜欢这么做。最后我想找点事情来拓宽自己的视野,于是就申请加入了 OCH 这里。一开始我有点紧张,因为这是一个全新的药学领域,但从那时起我就喜欢上了它。每一天都有不同的经历,比零售药店更加多样化。我真的很喜欢这里。

 OCH:您如何为我们的患者带来希望?

JC: 我认为在 Option Care Health 工作时,我最喜欢的部分之一就是在配药过程中看到患者的进展。我们科室配制了大量的儿科全肠外营养药物,我刚来科室的时候,有个新生儿每周七天都需要 TPN。新生儿的母亲当时承受着巨大的压力和焦虑。从患者开始在我们这里接受治疗服务到现在大概有两年了,如今他们每周只需要三天的 TPN 治疗。看到这些年来的进展确实很有意义。看到患者病情好转,从每周七天都需要 TPN 来维持生命,到可以通过食用正常食物和饮用正常饮品,从 TPN 袋以外的其他来源获得营养,这真的非常有意义。看到所需的剂量从七剂降到三剂,听到父母在熟悉如何照顾生病的孩子时的自信,真是令人欣喜。

JB:制作药物时,我们一周又一周地看到患者的姓名。我们并不真正了解患者,但我们确实知道他们的姓名。如果我们注意到有几周时间没见到患者的姓名,我们就会询问发生了什么事情。看到儿科患者因为病情好转或做了移植手术而不再需要我们的服务,真是件很棒的事。很高兴知道我们对他们的病情好转起到了一定的作用,我们为他们制作了安全的药物,为他们的护理做出了贡献。

CV:传递希望一直是我本人以及与我共事的其他药剂师的首要任务。传递希望不仅能让患者知道他们目前的状况,同时也让他们放心,OCH 公司正在计划让他们恢复健康并分享他们的情况。我们正在为这些患者发送药品,提供高水平的护理,确保他们接受适当的治疗,同时确保他们在家中的安全。

BV:我试着设身处地为他们着想。我们每天要帮助的人都是患者,他们的处境可能没有多少希望。因此,如果我们能让他们的事情变得容易些,并及时提供他们所需的药物,他们就不必担心,并且可以依靠 Option Care Health。这就是我们传递希望的方式。

在 Option Care Health 作为一名药房技术员/药剂师有什么特别之处?

JC:我最喜欢的部分是 TPN。我能够看到患者的病情进展,并且知道我个人正在影响他们的整体健康。我最近有幸做的一件事就是与我们的区域临床总监 (ACD) Craig 紧密合作。整个 OCH 都通过了 ACHC 认证调查,Craig 一直是很好的资源。他总是倾听技术人员的意见,认真考虑我们可能提出的任何建议、最佳做法、简化流程等。我一直在与他合作,更新 OCH 药房使用的一些表格,我非常自豪能与身为东北部 ACD 的他共事。

JB:药剂师和药房技术员彼此之间非常信任。他们监督我们的工作以确保准确性,但是在配制药物时我们是专家。我们知道拿着注射器的正确方法,我们知道典型的剂量是多少,我们知道如何重新配制药物。如果我们发现不寻常的情况,由于我们具有静脉注射方面的专业知识,我们会去找药剂师,告知他们,然后再继续。

CV:我在 OCH 拥有最好的领导层。我可以随时向他们寻求指导或帮助,以确保我们的分支机构拥有我们需要的一切。这一出色的领导层就是我们的特别之处,因为他们真正关心我们,并始终确保我们拥有一切,为患者提供优越的护理。这才是真正使我们与众不同的地方。

BV:我在这里拥有的不同机会带来了真正的改变。我觉得我们所有人都对公司有意义,对此我深表感谢。

OCH:告诉我,疫情期间在药房的环境工作情况如何?

JC: When the pandemic first hit, there was a lot of uncertainty throughout the country. Working in a sterile environment, it honestly became scary. One of the great things OCH did is that they started making sure that each facility was environmentally testing their room more frequently to ensure that our cleaning procedures were working effectively. This way, we ensured that we had removed the possibility of creating any room for additional bacteria to grow. At first, things were quite nerve-wracking but seeing that we’ve been environmentally testing our rooms with no positive cultures on any of these tests really goes to show how thoroughly the technicians pay attention to what they’re doing, and that they’re being extra cautious to ensure everything is sterile. The extra precautions that OCH has put into effect have eased a lot of that worry I had before.

JB:我们以前就很干净,现在清洁得更彻底了。我都不知道这是有可能的!很高兴知道我还能保住我的工作。当很多人不知道自己是否会被解雇,是否可以依靠自己的工资时,我很庆幸自己每周都有一份工资。令我感到非常欣慰的是,除了其他需要担心的事情,我的工作仍然很稳定。事实上,我们收到了一位妈妈的感谢信,她很担心她的孩子会如何接受我们的药物治疗,我们为她减轻了压力,这感觉非常好。我们为自己能够在所有不确定因素中提供适当的患者护理而感到自豪。

CV:新冠肺炎显然对全世界,尤其是对纽约市产生了巨大影响。疫情期间处于这一地区确实改变了医疗保健、我们对什么仍然保持一致的观点以及对即将发生的任何问题的看法。我们制定了政策和程序来始终确保团队成员的安全:保持社交距离和佩戴口罩以确保自己和家人的安全。处于疫情重灾区确实使我们能够更好地合作,因为我们意识到我们正在努力帮助人们,我们团结一致,在整个疫情期间支持其他人的需要。我很幸运能在纽约市的这个团队工作,每天为我们的患者提供护理。

BV:我对 OCH 应对疫情的方式倍感自豪。我们一意识到疫情重大,就立即开始储备每天需要用到的物资。我们开始着手更新政策和程序,不仅要保证员工的安全,还要确保患者的安全。Option Care Health 的领导层在准备和应对疫情方面做了非常出色的工作,因为疫情对我的个人生活几乎没有影响。

OCH:您有庆祝药学周的计划吗?

JC:我当时在 CMC 的想法是,我们也许可以协调一下我们的服装或其他有趣新颖的东西,以显示我们团结一致,以团队身份脱颖而出。我们真心享受确保我们的患者健康安全的工作。

JB:是的,我们打算在办公室四周贴满药房工作团队的照片,把他们的脸贴到超级英雄的身上,看看我们的团队成员中有多少人能够找出来,因为我们是超级英雄,希望能以这种方式来认可我们的团队成员。

CV:为了纪念这一具有里程碑意义的一年,我们将它作为“关键劳动者日”来庆祝,因为我们都发挥了重要作用。显然,药剂师和药房技术人员会脱颖而出,但我们要认可整个分支机构。我们的关键劳动者每天都来上班,从不间断地向患者传递希望,并确保我们采取适当的预防措施,在这个前所未有的时刻砥砺前行。

BV:我想我们打算和团队一起吃一顿美味的午餐。虽然一切局势有点紧张,但能有片刻的时间坐下来稍事放松,为自己庆祝一下,也是挺不错的。

OCH:“强健药房”(Pharmacy Strong) 对您意味着什么?

JC:“强健药房”不是个人的事情,我们日复一日的工作中都融入了大量的团队合作。包括药剂师在内,我们每天都必须共同努力,确保我们为患者的安全采取适当的措施。药房幕后的团队合作就是“强健药房”对我的意义。我们真心喜爱我们在 OCH 所做的事情,许许多多的迁移工作需要我们齐心协力,以确保我们的患者拥有积极的体验。

CV:对我来说成为强健药房”意味着我们所有人通力协作,拥有一个共同的团队目标:患者至上。我们齐心协力,团结合作,作为团队向患者提供最好的护理服务。

BV:我认为,我想,作为一个群体,我们都是坚强的个人。在药房工作时,大量任务可能会从各个方向接踵而来,这支团队非常出色。我可以信任每个人,我知道所有人每天都会来上班,并且付出 100% 的努力。我们可能会身挑重担,但我们都会挺身而出排忧解难,确保患者最终会得到照顾。

OCH:您最后还有什么想法要分享吗?

JC:在 OCH 工作,总体上我感觉还有很大的发展空间。总的来说,药学专业的发展空间很大,作为技术员会遇到很多不同的角色。在 OCH,我们就有仓库技术员、供送泵管理技术员、与患者联系的临床技术员以及配药技术员。药房技术员通常在 OCH 和药房中都有大量的表现机会。当你找到合适的职位时,就会有丰厚的回报,您在药学领域的发展将不受限制。

CV:充满激情的人员组成了这家公司,我们真心致力于为所有患者提供优越的护理。我们所有人在这里都竭尽所能,每天为患者提供护理,我相信这代表了我们整个组织。

BV:我想,我最想说的是,当你将 OCH 看成是一家公司和潜在的工作场所时,对于药剂师和药房技术员来说,这可能会让他们心生恐惧,因为这不同于他们以前工作过的任何地方。每天情况都不一样。你可以走进大门,并以你工作的地方为荣,热爱你的工作。抓住机会,终有回报。

随着新冠肺炎大流行继续改变基于家庭的护理行业,各机构为成功实现基于价值的护理模式而进行的变革已变得更加紧迫。创新技术对于优先考虑基于价值的数据以及无缝过渡到低成本护理环境至关重要。

出于经济和安全两方面的考虑,家庭护理在使老年人或免疫功能低下的患者的风险最小化方面发挥着越来越重要的作用,尤其是对于那些依赖于输注药物疗法治疗复杂慢性病症的患者。由于新冠肺炎大流行和对卫生系统环境中接触风险的担忧增加,医院系统的能力变得分散,因此让人们呆在舒适的家中的必要性比以往任何时候都更大。

这就是家庭输液疗法如此有吸引力的原因。

家庭输液有很多好处,但也面临着新冠肺炎带来的一系列新挑战。采用灵活、可扩展的技术是该解决方案的重要组成部分,用以支持面对面和虚拟操作,并建立不受新冠肺炎大流行影响的新流程。

凭借其所需的设备组合、复杂的治疗管理以及众多医疗服务提供者之间的临床协调,家庭输液在数据跟踪和运营效率方面遇到了压力。为了应对这些挑战,家庭和备选站点输液提供商需要一个基于云的移动软件平台,提供实时通信,并与其他系统无缝集成,为用户提供单点访问权限。

基于云的家庭医疗保健软件提供商 AlayaCare 的创始人兼首席执行官 Adrian Schauer 表示:“随着家庭输液需求的增长,确保患者安全和提供高质量护理将成为一个重点。”

在新冠肺炎大流行期间,基于云的技术带给家庭和备选站点输液治疗带来以下五个好处。

提供易于使用的技术

 对于 Option Care Health 来说,与 AlayaCare 的合作伙伴关系正是医生的要求。其主要优势之一是技术易用,这对于习惯使用纸笔的护理团队是一个关键卖点。

Option Care Health 护理副总裁 Joan Couden 说:“我们需要一种易于采用的解决方案,帮助我们轻松迁移到虚拟环境,满足日益增长的数据需求。IT 匹配对我们来说非常重要。我们选择的解决方案必须适合我们的其他系统并能满足临床需求。”

加强护士与药剂师的沟通与协作

 护士和药剂师之间的良好关系对于优化家庭输液效果十分重要。药剂师必须了解护理过程中发生的一切,而护士则必须清楚病人的所有口服药物以及药房配制和分配药物的情况。

Couden 说,在与 AlayaCare 合作之前,Option Care Health 通过人工流程来维持护士与药剂师之间的合作,这种人工流程“不是最优选择”。

取而代之的是,基于云的技术从护士到药房或从药房到护士近实时更新护理计划。更改用药或患者对药物的反应会立即传送出去。

Schauer 说:“现在,急性后期护理提供商必须将人工业务流程自动化,以确保高质量的护理,否则就有可能错过盈利增长的机会。”

 无论环境如何,都能提供一致的护理

 在当今这个流动性较强且新冠肺炎大流行和基于价值的世界中,人们欢迎低成本环境中的护理,在病人家中提供护理的能力极有价值,并且这对于护理效果和最终盈利都有多重好处。

但是,家中并不是我们提供输液服务的唯一场所。病人也可以在输液室接受治疗。基于云的技术可提供跨环境的连续性护理,以确保无论环境如何,护理质量都是相同的。

“在远程、移动的临床环境中存在很多挑战。AlayaCare 平台可以灵活、动态地适应家庭输液的传统运作方式和今天的变化,”Option Care Health 首席信息官 Brett Michalak 说。“每个人都可以专注于病人的临床护理,而不是底层的技术。这意味着通过这种合作伙伴关系可以极大地提高患者体验和治疗效果。”

Couden 补充说:“这项技术使我们能够专注于以最有效的方式提供护理。我们只需单击一下按钮,就可以确保为患者找到合适的护士,从而缩短出行时间并增加面对患者的时间。”

推进向远程医疗的转变

尽管此技术在新冠肺炎大流行之前就具有很大价值,但在大流行期间 Option Care Health 看到了其价值的巨大提升。基于云的技术为这一转变提供支持,这一转变在未来几个月可能会继续深化。

Couden 说:“新冠肺炎大流行让我们以不同方式看待我们所做的每一件事。当我们与 AlayaCare 一起开始这一旅程时,如果有人问我,'远程医疗是我们现在必须要做的事情吗?'我可能会说不是。但是,通过与 AlayaCare 和我们的临床团队合作伙伴关系,我们能够快速、顺利地部署虚拟解决方案,这些解决方案确实每次都能真正改变患者的生活。我相信,这是现在和未来如何继续提供医疗服务的一个重要组成部分。”

易于集成,可快速部署

护理人员对新技术系统最关注的问题之一是工作流。他们会问,整合新技术需要多长时间?无论护理人员已使用哪种技术,AlayaCare 的答案几乎都是即时即可整合。

“AlayaCare 使我们能够快速部署这项技术,” Michalak 说。“在我看来,其他同类平台无法提供 AlayaCare 所能提供的集成功能。平台的集成功能使得人们能够快速采用。”

在新冠肺炎流行期间,对快速集成和简化协作的需求显然很高,当 Option Care 去年被并购时(新公司更名为 Option Care Health),AlayaCare 的技术也帮助该公司快速转向。

Michalak 说:“平台的敏捷性使我们能够灵活地适应护理环境中的任何变化。无论是并购还是新冠肺炎大流行,我们都能以最优方式调整和部署技术,使我们的临床医生能够专注于护理而非管理技术。易用性和可扩展性让我们的临床医生能够发挥出他们的最高水平。”

要详细了解 AlayaCare 如何帮助家庭输液业务,请立即访问 AlayaCare.com

与 AlayaCare 合作伙伴关系撰写的文章,再次发布自 homehealthcarenews.com

BANNOCKBURN, Ill., Sept. 02, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, has been selected to participate in the limited distribution network of VILTEPSO™ (viltolarsen) for patients with Duchenne Muscular Dystrophy (“DMD”) who are amenable to exon 53 skipping therapy. Manufactured by NS Pharma, Inc., Viltepso is the first and only exon 53 skipping therapy to demonstrate an increase in dystrophin in patients as young as four years old.

Viltepso is among a growing number of chronic infusion therapies for neuromuscular disorders that Option Care Health is able to deliver to patients at home or in one of the company’s more than 125 ambulatory infusion suites across the country.

“NS Pharma selected Option Care Health as an option to distribute and administer Viltepso, which offers hope to patients with this devastating disease and their caregivers, because of our reputation of providing extraordinary care,” said Matt Deans, Senior Vice President of Business Development at Option Care Health. “Our demonstrated track record of collaboration with manufacturers to extend infusion services for new therapies to alternate treatment sites, coupled with our personalized clinical care, leads to better outcomes and higher patient satisfaction.”

DMD is an inherited progressive neurological disorder that primarily affects boys because it is located on the X chromosome (male gene). It is caused by genetic mutations that prevent the production of dystrophin, a key protein for supporting muscle health. Symptoms appear as early as two years of age and typically progresses to cardiac and respiratory muscle problems beginning in the patient’s teenage years, leading to serious, life-threatening complications.

Increasing dystrophin as much and as early as possible has become a key goal in the treatment of DMD. Viltepso received an Accelerated Approval by the Food and Drug Administration (FDA) based on an increase in dystrophin in patients with DMD who are amenable to exon 53 skipping therapy; exon 53 skipping is applicable in about 8% of the DMD population.

“We chose to include Option Care Health in our distribution network because of its commitment to providing excellent clinical care and national footprint,” said Gardner Gendron, Chief Commercial Officer at NS Pharma. “Its expertise in providing infusions for complex neuromuscular conditions, broad access to insurance networks and service in all 50 states give us the confidence that our patients will be able to receive Viltepso.”

Viltepso 的推荐剂量为 80mg/kg,由在该疾病和治疗方面经过专门培训的 Option Care Health 护士每周静脉注射一次,每次超过 60 分钟。Option Care Health 与提供者密切合作,以制定定制的患者护理计划并提供定期治疗更新。患者接受了广泛的教育,如果有疑问或需要支持,可以随时联系经验丰富的临床医师。

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including approximately 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is re-imagining the infusion care experience for patients, customers and employees. To learn more, please visit our website at OptionCareHealth.com.

About NS Pharma, Inc.

NS Pharma, Inc. 是 Nippon Shinyaku Co., Ltd. 的全资子公司。要了解更多信息,请访问 http://www.nspharma.com。NS Pharma 和 Viltepso 是 Nippon Shinyaku 集团公司的注册商标。

前瞻性声明 – 安全港

本新闻稿可能包含 1995 年《美国私人证券诉讼改革法案》安全港条款所定义的“前瞻性声明”。前瞻性声明可以用诸如“预计”、“打算”、“计划”、“相信”、“项目”、“估计”、“预期”、“可能”、“应该”、“将要”以及对未来时期的类似提法来识别。前瞻性声明的例子包括但不限于,我们可能就未来收入、未来收益、监管发展、市场发展、新产品和增长战略、整合活动以及上述任何一项对我们未来经营业绩或财务状况的影响所作的陈述。

前瞻性声明既不是历史事实,也不是对未来业绩的保证。相反,它们只是基于我们当前对公司业务的未来、未来计划和战略、预测、预期事件和趋势、经济以及其他未来条件的信念、期望和假设。由于前瞻性声明与未来相关,因此它们受到固有的不确定性、风险和情况变化的影响,这些情况难以预测,其中许多是我们无法控制的情况。我们的实际结果和财务状况可能会与前瞻性声明中的内容存在重大差异。可能导致我们的实际结果和财务状况与前瞻性声明中的陈述存在重大差异的重要因素包括但不限于:(i) 适用于我们业务模式的法律和法规的变更;(ii) 市场状况以及对我们服务和产品的接受度的变化; (iii) 诉讼结果;(iv) 一家或多家主要支付方的损失; (v) 新冠疫情的传播和影响。有关可能影响我们实际结果的风险因素的详细讨论,请参阅美国证券交易委员会 (SEC) 报告中确定的风险因素,包括但不限于我们向 SEC 提交的 10-K 报表年度报告和 10-Q 报表季度报告。

我们在本新闻稿中所作的任何前瞻性声明仅基于我们当前可获得的信息,并且仅以发表之日为准。无论是书面形式还是口头形式,不管是由于新的信息、未来的发展还是其他原因,我们均不承担公开更新任何前瞻性声明的义务。

对于罕见的难治性尿路癌,首个免手术治疗方案需要复杂的临床方案

BANNOCKBURN, Ill., May 21, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, has been selected by UroGen Pharma (NASDAQ: URGN) as a preferred national pharmacy provider to prepare and deliver a first-of-its-kind cancer treatment, Jelmyto™ (mitomycin) for pyelocalyceal solution.

新制剂为治疗成人低度上尿路癌 (LG-UTUC) 提供了一种新的方法,用一种随着温度变化而改变形态的药物直接靶向肿瘤,并且必须在制备后八小时内由医生提供。为了确保药物在规定的时间内按照产品标签要求和药房标准进行制备、运输并提供给患者,Option Care Health 与 UroGen 合作,创建了一个创新的药房解决方案,通过其遍布全国的无菌配药药房和分销网络来支持 Jelmyto

Jelmyto 于 2020 年 4 月 15 日获得美国食品药品监督管理局的批准,是使用 UroGen 专有的 RTGel™ 缓释技术由丝裂霉素(一种成熟的化学疗法)和无菌水凝胶组成的一流疗法。它的设计目的是使泌尿道组织长时间暴露于丝裂霉素,从而通过非手术、保肾的方法促进对这些罕见且难以治疗的癌性肿瘤的治疗。

Jelmyto 必须在符合 USP 800 标准的药房中制备,这些药房采用更高的质量和安全标准,除了配药室外,还必须有更多的能力和专业知识来处理细胞毒性药物成分。Option Care Health 的全国 USP 800 药房网络将根据患者的特定 Jelmyto 处方制备配方,并在规定的时间内按照 Jelmyto 药房说明书的严格标准将其交付给泌尿科医生。  

“Option Care Health 在符合 USP 800 标准的药房网络中的基础设施和配药能力是无与伦比的,这使我们能够与 UroGen 公司合作提供全面的服务。”Option Care Health 公司总裁兼首席执行官 John C. Rademacher 说道。“每天,Option Care Health 都会确保成千上万的患者安全、及时地接受所需的治疗。我们在临床基础设施方面进行的投资使我们能够与 UroGen 合作,提供这种创新的新疗法。”

“UroGen 正在通过新型的非手术治疗替代方案(如 Jelmyto)挑战护理标准,这利用了我们在特种癌症和泌尿系统疾病方面的创新技术和专业知识,”UroGen 总裁兼首席执行官 Liz Barrett 说道。“Jelmyto 需要复杂的制备和及时的交付,而 Option Care Health 提供了我们要求合作伙伴所具备的全国规模、经验深度、专业知识和对质量的承诺,以确保患者及时安全地接受这种重要的新疗法。”

LG-UTUC 是一种罕见的癌症,发病于上尿路、输尿管和肾脏的内膜。每年约有 6,000 至 7,000 名美国患者被诊断为新发性或复发性 LG-UTUC。由于泌尿系统解剖结构复杂,治疗难度大。目前的标准护理包括多种手术,通常是根治性肾输尿管切除术,包括切除肾盂、肾脏、输尿管和膀胱袖带。

About Option Care Health

Option Care Health 是全美最大的家庭和备选站点输液服务的独立提供商。我们拥有 5,000 多名团队成员,其中包括约 2,900 名临床医生,我们在工作中饱含同情心,致力于提高所有 50 个州的急性和慢性病症患者的护理标准。通过我们的临床领导能力、专业知识和全国规模,Option Care Health 正在为患者、客户和员工重新构筑输液护理体验。要了解更多信息,请访问我们的网站 OptionCareHealth.com

关于 UroGen Pharma Ltd.
UroGen 是一家生物制药公司,致力于打造治疗特种癌症和泌尿系统疾病的新型解决方案,因为患者值得拥有更好的选择。UroGen 开发了 RTGel™ 逆热水凝胶,这是一种基于水凝胶的专有缓释平台技术,有可能改善现有药物的治疗情况。UroGen 的持续释放技术旨在使尿路组织暴露在药物中的时间更长,从而使局部治疗成为潜在的更有效的治疗选择。UroGen 获得批准的肾盂积水溶液 Jelmyto™ (丝裂霉素)和膀胱内溶液的 UGN-102(丝裂霉素)管道治疗旨在通过非手术方式消融肿瘤并治疗多种形式的非肌肉浸润性尿路上皮癌,包括低度恶性上尿路尿路上皮癌和低度非肌肉浸润性膀胱癌。UroGen 的总部位于新泽西州普林斯顿市,在以色列设有业务部门。访问 www.urogen.com 了解更多信息或在 Twitter 上关注我们 @UroGenPharma

前瞻性声明 – 安全港

本新闻稿可能包含 1995 年《美国私人证券诉讼改革法案》安全港条款所定义的“前瞻性声明”。前瞻性声明可以用诸如“预计”、“打算”、“计划”、“相信”、“项目”、“估计”、“预期”、“可能”、“应该”、“将要”以及对未来时期的类似提法来识别。前瞻性声明的例子包括但不限于,我们可能就未来收入、未来收益、监管发展、市场发展、新产品和增长战略、整合活动以及上述任何一项对我们未来经营业绩或财务状况的影响所作的陈述。

前瞻性声明既不是历史事实,也不是对未来业绩的保证。相反,它们只是基于我们当前对公司业务的未来、未来计划和战略、预测、预期事件和趋势、经济以及其他未来条件的信念、期望和假设。由于前瞻性声明与未来相关,因此它们受到固有的不确定性、风险和情况变化的影响,这些情况难以预测,其中许多是我们无法控制的情况。我们的实际结果和财务状况可能会与前瞻性声明中的内容存在重大差异。可能导致我们的实际结果和财务状况与前瞻性声明中的陈述存在重大差异的重要因素包括但不限于:(i) 适用于我们业务模式的法律和法规的变更;(ii) 市场状况以及对我们服务和产品的接受度的变化; (iii) 诉讼结果;(iv) 一家或多家主要支付方的损失; (v) 新冠疫情的传播和影响。有关可能影响我们实际结果的风险因素的详细讨论,请参阅美国证券交易委员会 (SEC) 报告中确定的风险因素,包括但不限于我们向 SEC 提交的 10-K 报表年度报告和 10-Q 报表季度报告。

我们在本新闻稿中所作的任何前瞻性声明仅基于我们当前可获得的信息,并且仅以发表之日为准。无论是书面形式还是口头形式,不管是由于新的信息、未来的发展还是其他原因,我们均不承担公开更新任何前瞻性声明的义务。